|Day Low/High||110.70 / 112.87|
|52 Wk Low/High||82.77 / 122.15|
Let's see what the charts have to say.
After correction, the medical device maker could see longer-term gains to the $150-$161 area.
Top picks in the fast-growing medical products market.
Evaluating the market and policy discussion ahead of Jackson Hole, and how I am playing Zscaler on this weakness.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Let's check the charts and indicators on the glucose-monitoring company.
Amid May's market turbulence, the RMPIA was buoyed by the more than 4% rise from Medtronic.
No one knows their business as well as the CEO.
China's President Xi has obviously found surrender distasteful.
In this day and age, companies must be 'disruptors' or get left in the dust.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
These eight S&P 500 stocks have some of the worst returns year-to-date and represent a diverse roster of promising bounce candidates.
Prices are testing the October and November lows and also testing the rising 200-day moving average line.
Everyone gets knocked down. What is different about you is that you are as tough as these markets.
Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.
PepsiCo, GE and just like the weather, the stock market is subject to change.
Straying from these names could land you in quicksand as the 4th quarter begins.
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
LULU is up 70% since March. This is how to get into the name in an intelligent way.
It is all about perception, and here are strong names to pick up on market weakness.
Tech and retail gains aren't enough to lead markets to new highs.
The crash of oil will only accelerate the move.
Charts say the medical-devices firm should have a price target 16% above current levels, but one indicator fails to confirm that.